XJPX4593
Market cap134mUSD
Jan 16, Last price
231.00JPY
1D
15.50%
1Q
9.48%
Jan 2017
-89.35%
IPO
-84.60%
Name
Healios KK
Chart & Performance
P/E
—
P/S
172.07
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
6.67%
Rev. gr., 5y
26.61%
Revenues
121m
+34.44%
Net income
-3.82b
L-26.05%
CFO
-2.82b
L-38.67%
Profile
Healios K.K. engages in the research and development, manufacture, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company is also developing cellular and tissue-based products comprising HLCR011 and HLCR012 that are iPSC regenerative medicines for the treatment of age-related macular degeneration; HLCL041, an iPSC regenerative medicine for the treatment of metabolic liver disease; and HLCM051, a regenerative medicine for treatment of ischemic stroke and acute respiratory distress syndrome, as well as HLCN061 for treating solid tumors. Healios K.K. has a joint research agreement with the Hyogo Medical University on cancer immunotherapies for mesothelioma using eNK cells. The company was formerly known as Retina Institute Japan, K.K. and changed its name to Healios K.K. in September 2013. Healios K.K. was incorporated in 2011 and is headquartered in Tokyo, Japan.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 121,000 34.44% | 90,000 119.51% | |||||||
Cost of revenue | 3,501,000 | 5,257,000 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (3,380,000) | (5,167,000) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | 187,000 | (160,000) | |||||||
Tax Rate | |||||||||
NOPAT | (3,567,000) | (5,007,000) | |||||||
Net income | (3,823,000) -26.05% | (5,170,000) 5.25% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 3,115,000 | 2,217,000 | |||||||
BB yield | -27.76% | -14.51% | |||||||
| Debt | |||||||||
Debt current | 4,082,000 | 3,135,000 | |||||||
Long-term debt | 575,000 | 4,270,000 | |||||||
Deferred revenue | 659,000 | 686,000 | |||||||
Other long-term liabilities | 3,825,000 | 1,141,000 | |||||||
Net debt | (4,660,000) | (1,399,000) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (2,822,000) | (4,601,000) | |||||||
CAPEX | (25,000) | (262,000) | |||||||
Cash from investing activities | (1,121,000) | (909,000) | |||||||
Cash from financing activities | 3,337,000 | (2,502,000) | |||||||
FCF | (2,763,000) | (5,213,000) | |||||||
| Balance | |||||||||
Cash | 6,722,000 | 7,324,000 | |||||||
Long term investments | 2,595,000 | 1,480,000 | |||||||
Excess cash | 9,310,950 | 8,799,500 | |||||||
Stockholders' equity | 3,355,000 | 2,180,000 | |||||||
Invested Capital | 9,529,000 | 11,140,000 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 68,004 | 57,010 | |||||||
Price | 165.00 -38.43% | 268.00 -79.11% | |||||||
Market cap | 11,220,693 -26.56% | 15,278,775 -77.36% | |||||||
EV | 6,572,693 | 16,858,775 | |||||||
EBITDA | (3,007,000) | (4,781,000) | |||||||
EV/EBITDA | |||||||||
Interest | 704,000 | 500,000 | |||||||
Interest/NOPBT | |||||||||